Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Hayato Koba"'
Autor:
Hayato Koba, Taro Yoneda, Hiroko Morita, Hideharu Kimura, Yuya Murase, Nanao Terada, Yuichi Tambo, Masafumi Horie, Kazuo Kasahara, Isao Matsumoto, Seiji Yano
Publikováno v:
Thoracic Cancer, Vol 15, Iss 8, Pp 661-666 (2024)
Abstract Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is crucial for patients with lung cancer harboring EGFR mutations. However, almost all patients experience disease progression, regardless of their response to the targe
Externí odkaz:
https://doaj.org/article/af7ce787e5bc4d3ebe70309ad5c2ea41
Autor:
Hayato Koba, Hideharu Kimura, Taro Yoneda, Takashi Sone, Noriyuki Ohkura, Johsuke Hara, Kazuyoshi Hosomichi, Atsushi Tajima, Kazuo Kasahara
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
Abstract In cancer patients, circulating cell-free DNA (cfDNA) includes tumor-derived DNA (tDNA). cfDNA has been used clinically for non-invasive gene mutation testing. The aim of this study was to characterize the features of the genetic alterations
Externí odkaz:
https://doaj.org/article/ad43e947b89543268697b1f2e5f2c70a
Publikováno v:
Clinical Case Reports, Vol 8, Iss 12, Pp 3142-3147 (2020)
Key Clinical Message The combination therapy of Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID‐19. Serum ferritin levels and lymphocytopenia are promising markers for disease severity and disease progressio
Externí odkaz:
https://doaj.org/article/827d848d41bb492f8fd155f6417d3ddb
Autor:
Kazuyuki Kakeshita, Taro Yoneda, Hayato Koba, Kota Tanimura, Tsukasa Ueda, Tomoya Kaneda, Johsuke Hara, Kazuo Kasahara
Publikováno v:
Clinical Case Reports, Vol 8, Iss 10, Pp 1872-1876 (2020)
Abstract We presented a rare case of pulmonary arteriovenous fistula in a patient who suffered from migraine with optic aura for longer than 20 years. This case suggests that the migraine could be expected to disappear after treatment for pulmonary a
Externí odkaz:
https://doaj.org/article/6e09a33a1ed84cdc85f8697a9c05e271
Autor:
Hideharu Kimura, Tomoyuki Araya, Taro Yoneda, Hiroki Shirasaki, Koji Kurokawa, Tamami Sakai, Hayato Koba, Yuichi Tambo, Shingo Nishikawa, Takashi Sone, Kazuo Kasahara
Publikováno v:
Cancer Communications, Vol 39, Iss 1, Pp 1-5 (2019)
Externí odkaz:
https://doaj.org/article/f61bff6ab2a94e97a08070aa2ef73cc1
Autor:
Hideharu Kimura, Yoshiaki Amino, Hayato Koba, Yuichi Tambo, Noriyuki Ohkura, Johsuke Hara, Takashi Sone, Kazuo Kasahara
Publikováno v:
Cancer Communications, Vol 39, Iss 1, Pp 1-5 (2019)
Externí odkaz:
https://doaj.org/article/d49b7bdc230c42679b9d0d60ecbf74c3
Autor:
Hayato Koba, Taro Yoneda, Hiroko Morita, Tsukasa Ueda, Ryo Hara, Nanao Terada, Mako Miyakawa, Hideharu Kimura, Kazuo Kasahara
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 4, Iss , Pp 100116- (2021)
Immune monotherapy is ineffective for oncogene-addicted lung cancer. This study reported the case of a patient with lung cancer harboring an epidermal growth factor receptor (EGFR) mutation that recurred after treatment with afatinib, a tyrosine kina
Externí odkaz:
https://doaj.org/article/5708e686db704040a92c3bf64a205688
Autor:
Wakana Takahashi, Taro Yoneda, Hayato Koba, Tsukasa Ueda, Noriaki Tsuji, Haruhiko Ogawa, Hidesaku Asakura
Publikováno v:
International Journal of Infectious Diseases, Vol 102, Iss , Pp 529-531 (2021)
Nafamostat, a serine proteinase inhibitor with various actions including antithrombin, antiplasmin, and antitrypsin effects, has been used in clinical practice to treat disseminated intravascular coagulation (DIC) and pancreatitis. This case report d
Externí odkaz:
https://doaj.org/article/11755674d954467ebb3fc07b23b3e48a
Autor:
Taro Yoneda, Takashi Sone, Hayato Koba, Kazuhiko Shibata, Junya Suzuki, Mayuko Tani, Masaru Nishitsuji, Koichi Nishi, Takafumi Kobayashi, Hiroki Shirasaki, Tomoyuki Araya, Toshiyuki Kita, Kazumasa Kase, Kenta Yamamura, Nanao Terada, Shingo Nishikawa, Yuichi Tambo, Hideharu Kimura, Kazuo Kasahara
Publikováno v:
Clinical Lung Cancer. 23:467-476
Immune checkpoint inhibitor (ICI) monotherapy is more effective than cytotoxic chemotherapy in improving overall survival (OS) among patients with advanced-stage non-small cell lung cancer (NSCLC). Recently, chemotherapy combined with ICI has been fo
Autor:
Kazuo Kasahara, Naohiko Ogawa, Kota Tanimura, Yuichi Tambo, Atsushi Tajima, Takashi Sone, Hideharu Kimura, Taro Yoneda, Kazuyoshi Hosomichi, Hayato Koba
Publikováno v:
Transl Lung Cancer Res
BACKGROUND: Molecular targeted therapy has been developed as an innovative treatment for metastatic cancer. Epidermal growth factor receptor (EGFR) mutation is one of the most important and frequent oncogenic drivers in non-small-cell lung cancer, an